STRENGTHENING DRUG SAFETY ON A GLOBAL SCALE: PRACTICE AND PROSPECTS
- Authors
-
-
Sattorova Marjona Matxiddin qizi
2nd-Year Student, Faculty of Pharmacy, Pharmacy Direction, Tashkent Pharmaceutical Institute
Author
-
Raximov Muxammadamin Olimjon o'g'li
5th-Year Student, Faculty of Pharmacy, Clinical Pharmacy Direction, Tashkent Pharmaceutical Institute
Author
-
Omonova Sevinch Oybek qizi
2nd-Year Student, Faculty of Industrial Pharmacy, Industrial Pharmacy direction, Tashkent Pharmaceutical Institute
Author
-
Ibadullayeva Farida Bahrom qizi
2nd-Year Student, Faculty of Pharmacy, Pharmacy Direction, Tashkent Pharmaceutical Institute
Author
-
- Keywords:
- drug safety, pharmacovigilance, WHO, ICH, good manufacturing practice, falsified medicines, regulatory harmonization, adverse drug reactions, global health.
- Abstract
-
Drug safety has become one of the central priorities of public health systems worldwide, as the globalization of pharmaceutical manufacturing, distribution, and trade has multiplied the pathways through which unsafe, substandard, or falsified medicines can reach patients. This article examines the current state of global drug safety practice, including international regulatory harmonization efforts led by the World Health Organization (WHO) and the International Council for Harmonisation (ICH), national pharmacovigilance systems, good manufacturing and distribution practices, and the ongoing struggle against substandard and falsified medical products. Particular attention is given to the role of digital technologies, artificial intelligence, and track-and-trace systems in modernizing adverse-event monitoring and supply-chain security. The article concludes with an assessment of prospective directions for strengthening drug safety, including deeper international cooperation, capacity building in low- and middle-income countries, and the harmonization of regulatory standards. The analysis is intended to be useful for pharmacy students, practicing pharmacists, and regulatory professionals seeking a concise overview of global drug safety practice and its future trajectory.
- References
-
1. World Health Organization. Global Patient Safety Report 2024. Geneva: WHO; 2024. ISBN 9789240095458.
2. World Health Organization. Global Surveillance and Monitoring System for substandard and falsified medical products: activity report, August 2017–December 2021. Geneva: WHO; 2022.
3. World Health Organization. Substandard and falsified medical products [fact sheet]. Geneva: WHO; updated 2024.
4. World Health Organization. A study on the public health and socioeconomic impact of substandard or falsified medical products. Geneva: WHO; 2017.
5. World Health Organization. Report of existing technologies used to screen and detect substandard and falsified medical products. Geneva: WHO; 2025.
6. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Guidelines: Quality, Safety, Efficacy and Multidisciplinary. Geneva: ICH Secretariat.
7. Pharmaceutical Inspection Co-operation Scheme (PIC/S). About PIC/S: Harmonising GMP inspection standards. Geneva: PIC/S Secretariat.
8. Ndagije HB, et al. Adverse drug reaction reporting with the Med Safety app in Uganda: a cluster-randomised controlled trial. The Lancet Global Health. 2025.
9. Ozawa S, Evans DR, Bessias S, et al. Prevalence and estimated economic burden of substandard and falsified medicines in low- and middle-income countries: a systematic review and meta-analysis. JAMA Network Open. 2018.
- Downloads
- Published
- 2026-06-09
- Issue
- Vol. 2 No. 6 (2026)
- Section
- Articles
- License
-
This work is licensed under a Creative Commons Attribution 4.0 International License.
